Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | GGT1 | P19440 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1881832 | 1.00 | OPRK1 (0.48) | OPRK1METAP2METAP1TSHRMEN1 | |
| SCHEMBL1878857 | 0.87 | SIGMAR1 (0.51) | TSHRMEN1KMT2ASIGMAR1CA12 | |
| SCHEMBL2852582 | 0.75 | PPARG (0.49) | METAP2METAP1TSHRMEN1KMT2A | |
| SCHEMBL9676351 | 0.75 | SIGMAR1 (0.52) | OPRK1TSHRMEN1KMT2ACNR2 | |
| SCHEMBL2854668 | 0.75 | PPARG (0.49) | METAP2METAP1TSHRMEN1KMT2A | |
| Cadaverine Tartrate SCHEMBL3721240 | 0.74 | FFAR1 (0.56) | TSHRCYP1A2PPARGPPARA | |
| SCHEMBL3841362 | 0.73 | CTSK (0.57) | CA12PPARGPPARA | |
| SCHEMBL5850035 | 0.73 | CTSK (0.57) | CA12PPARGPPARA | |
| SCHEMBL5848452 | 0.73 | METAP2 (0.65) | METAP2METAP1PPARGPPARA | |
| SCHEMBL5848773 | 0.73 | METAP2 (0.65) | METAP2METAP1PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050738-B1 | NOVEL IMIDAZOLIDINONE DERIVATIVE, METHOD OF PRODUCING THE SAME AND METHOD OF PRODUCING OPTICALLY ACTIVE AMINO ACID | KANEKA CORP (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-7947722-B2 | Imidazolidinone derivative, method of producing the same and method of producing optically active amino acid | KANEKA CORPORATION (JP) | 2011-05-24 | — | — | US | disclosed |
| US-20090209768-A1 | NOVEL IMIDAZOLIDINONE DERIVATIVE, METHOD OF PRODUCING THE SAME AND METHOD OF PRODUCING OPTICALLY ACTIVE AMINO ACID | KANEKA CORPORATION (JP) | 2009-08-20 | — | — | US | disclosed |
| EP-2050738-A1 | NOVEL IMIDAZOLIDINONE DERIVATIVE, METHOD OF PRODUCING THE SAME AND METHOD OF PRODUCING OPTICALLY ACTIVE AMINO ACID | Kaneka Corporation (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209768-A1 | NOVEL IMIDAZOLIDINONE DERIVATIVE, METHOD OF PRODUCING THE SAME AND METHOD OF PRODUCING OPTICALLY ACTIVE AMINO ACID | DAO, RCC2, AADAT | OPRK1 2254/4885METAP2 451/4885METAP1 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.